Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Navdeep Singh

Showing results (181-190 of 183) with videos related to

Pageof 19
Sort By:
You have reached the last page of results.This site can display upto 183 results.
Cancers|May 14, 2022
RR Myelo POINT: A Retrospective Single-Center Study Assessing the Role of Radiotherapy in the Management of Multiple Myeloma and Possible Interactions with Concurrent Systemic TreatmentAndrea Emanuele Guerini, Alessandra Tucci, Filippo Alongi, et al.
Frontiers in Oncology|July 20, 2023
Unresectable stage III non-small cell lung cancer: could durvalumab be safe and effective in real-life clinical scenarios? Results of a single-center experiencePaolo Borghetti, Giulia Volpi, Giorgio Facheris, et al.
Frontiers in Oncology|November 10, 2022
Anal squamous cell carcinoma: Impact of radiochemotherapy evolution over years and an explorative analysis of MRI prediction of tumor response in a mono-institutional series of 131 patientsMarco Lorenzo Bonù, Salvatore La Mattina, Navdeep Singh, et al.
Pageof 19

Showing results (181-190 of 183) with videos related to

Sort By:
Pageof 19
You have reached the last page of results.This site can display upto 183 results.
Cancers|May 14, 2022
RR Myelo POINT: A Retrospective Single-Center Study Assessing the Role of Radiotherapy in the Management of Multiple Myeloma and Possible Interactions with Concurrent Systemic TreatmentAndrea Emanuele Guerini, Alessandra Tucci, Filippo Alongi, et al.
Frontiers in Oncology|July 20, 2023
Unresectable stage III non-small cell lung cancer: could durvalumab be safe and effective in real-life clinical scenarios? Results of a single-center experiencePaolo Borghetti, Giulia Volpi, Giorgio Facheris, et al.
Frontiers in Oncology|November 10, 2022
Anal squamous cell carcinoma: Impact of radiochemotherapy evolution over years and an explorative analysis of MRI prediction of tumor response in a mono-institutional series of 131 patientsMarco Lorenzo Bonù, Salvatore La Mattina, Navdeep Singh, et al.
Pageof 19